Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + nab-paclitaxel is a combination chemotherapy regimen primarily used for the treatment of advanced or metastatic pancreatic adenocarcinoma. Gemcitabine (Gemzar) is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing cells. Nab-paclitaxel (Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel, which stabilizes microtubules and prevents their disassembly, thereby inhibiting cell division. Nab-paclitaxel exploits albumin-mediated transport mechanisms to enhance drug delivery to tumors. The combination has demonstrated improved overall survival compared to gemcitabine alone in clinical trials for pancreatic cancer. Mechanistically, preclinical studies suggest that nab-paclitaxel may increase intratumoral concentrations of gemcitabine by reducing levels of cytidine deaminase, the enzyme responsible for metabolizing gemcitabine[3][4][6].
- Brand names
- Abraxane (for nab-paclitaxel)Gemzar (for gemcitabine)
- Other names
- gemcitabine and nab-paclitaxelgemcitabine plus nab-paclitaxelGemzar and Abraxane
02
Targets
MicrotubuleDNA polymerase family
Beyond the preview
Go deeper on gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + nab-paclitaxel.